$MCUR: MDMA for female sexual dysfunction. Low sex drive is not a pathology in itself, but the condition can become problematic when it triggers significant levels of personal distress, which can involve sadness, a sense of grief, and feelings of incompetence, loss and frustration.
According to MindCure, the hypoactive sexual desire disorder affects “10% of adult women and 14% of premenopausal adult women, all reporting that their low desire results in a state of distress.”
In the U.S. the condition is believed to affect an estimated 9.5 million premenopausal women.
Ramsden says there are currently two available drugs in the market targeting this indication, both of which are aimed at women’s physiology instead of addressing the psychological causes behind the condition. Their success rate goes only about 10% above placebo.
$OTLC: AL-101 drug for Female Sexual Dysfunction (FSD). FSD is a prevalent problem, afflicting approximately 40% of women and there are few available treatment options. FSD is more typical as women age, and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematologicalagents in medicinalchemistry, 7(4), 260-269). There is no available drug for the treatment of FSD. HSDD is characterized by a low sexual desire, that causes marked distress or interpersonal difficulty, and is not due to a co-existing medical or psychiatric condition, problems within the relationship or the effects of a medication or other drug substance. HSDD affects approximately 5.8 million U.S. premenopausal women (1 in 10 premenopausal women). Almost 98%, approximately 5.7 million of affected premenopausal women are not on any therapy for HSDD, either due to lack of education or lack of therapies available. One in 10 premenopausal women have low desire with associated distress. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized HSDD in premenopausal women. Currently, this is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD - however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopalepisodes. Therefore, there is an urgent need for an effective therapy against FSD and HSDD.
Submitted October 07, 2021 at 09:15AM by pinkonion477 https://ift.tt/3DjKkyB
